A bacterial protein enhances the release and efficacy of liposomal cancer drugs

Science

Volumn 314, Issue 5803, 2006, Pages 1308-1311

  Cheong, Ian ^a   Huang, Xin ^a   Bettegowda, Chetan ^a   Diaz Jr , Luis A ^a   Kinzler, Kenneth W ^a   Zhou, Shibin ^a   Vogelstein, Bert ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA; CELLS; CHEMOTHERAPY; DRUG PRODUCTS; ONCOLOGY; TUMORS;

BACTERIAL PROTEINS; LIPOSOMAL CANCER DRUGS; LIPOSOMAL DOXORUBICIN; LIPOSOME-ENCAPSULATED DRUGS;

PROTEINS;

ANTINEOPLASTIC AGENT; BACTERIAL PROTEIN; BEVACIZUMAB; DOXORUBICIN; IMATINIB; IRINOTECAN; LIPOSOMASE; LIPOSOME; UNCLASSIFIED DRUG;

BACTERIUM; CANCER; DISEASE TREATMENT; EXPERIMENTAL STUDY; PROTEIN; TUMOR;

ANAEROBIC BACTERIUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL SPORE; BACTERIUM MUTANT; CANCER REGRESSION; CLOSTRIDIUM; CLOSTRIDIUM NOVYI; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG RELEASE; ERADICATION THERAPY; HEMOLYSIS; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIAL PROTEINS; BASE SEQUENCE; CAMPTOTHECIN; CELL LINE, TUMOR; CLONING, MOLECULAR; CLOSTRIDIUM; COLORECTAL NEOPLASMS; DOXORUBICIN; DRUG CARRIERS; HUMANS; LIPASE; LIPID BILAYERS; LIPOSOMES; MICE; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM TRANSPLANTATION; PROTEIN STRUCTURE, TERTIARY;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM NOVYI;

EID: 33751586094     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1130651     Document Type: Article

References (20)

1. D. D. Von Hoff, A.-R. Hanauske, in Cancer Mediane, D. W. Kufe et al., Eds. (BC Decker, London, 2006), pp. 600-616.
2. C. Sawyers, Nature 432, 294 (2004).
3. S. V. Govindan, G. L. Griffiths, H. J. Hansen, I. D. Horak, D. M. Goldenberg, Technol. Cancer Res. Treat. 4, 37S (2005).
4. M. Yamamoto, D. T. Curiel, Technol. Cancer Res. Treat. 4, 315 (2005).
5. R. Kerbel, J. Folkman, Nat. Rev. Cancer 2, 727 (2002).
6. R. K. Jain, D. G. Duda, J. W. Clark, J. S. Loeffler, Nat. Clin. Pract. Oncol. 3, 24 (2006).
7. G. Thurston et al., J. Clin. Invest. 101, 1401 (1998).
8. H. Hashizume et al., Am. J. Pathal. 156, 1363 (2000).
9. D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, D. Papahadjopoulos, Pharmacol. Rev. 51, 691 (1999).
10. J. Fang, T. Sawa, H. Maeda, Adv. Exp. Med. Biol. 519, 29 (2003).
11. R. M. Ryan, J. Green, C. E. Lewis, Bioessays 28, 84 (2006).
12. S. Barbe, L. Van Mellaert, J. Anne, J. Appl. Microbiol. 101, 571 (2006).
13. J. Sakurai, M. Nagahama, M. Oda, J. Biochem. (Tokyo) 136, 569 (2004).
14. D. Papahadjopoulos et al., Proc. Natl. Acad. Sci. U.S.A. 88, 11460 (1991).
15. L. H. Dang, C. Bettegowda, D. L. Huso, K. W. Kinzler, B. Vogelstein, Proc. Natl. Acad. Sci. U.S.A. 98, 15155 (2001); published online 27 November 2001.
16. N. Agrawal et al., Proc. Natl. Acad. Sci. U.S.A. 101, 15172 (2004).
17. C. Bettegowda et al., Nat. Biotechnol., in press.
18. Materials and methods are available as supporting material on Science Online.
19. K. E. Jaeger, B. W. Dijkstra, M. T. Reetz, Annu. Rev. Microbial. 53, 315 (1999).
20. We thank L. Watson for assistance with animal experiments, S. Szabo for sequencing, D. Mamelak for assistance with proteomic analysis, K. Leong for advice on particle sizing, and P. Singh and S. Chandran for advice on fluorescence polarization. This work was supported by the Virginia and D. K. Ludwig Fund for Cancer Research, the Commonwealth Foundation, the Miracle Foundation, and NIH grant CA062924.